癌症代谢与质瘤表观遗传途径的整合和交叉
Siva Kumar Natarajan1,2, Matthew Pun1,2,3, James Haggerty-Skeans1,2,3
11Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA;
Annual review of pathology
|November 18, 2025
概括
质瘤的发展是由代谢学和表观遗传学之间的相互作用驱动的. 针对这些代谢途径为成人和儿科质瘤提供了新的治疗策略.
科学领域:
- 神经瘤学神经瘤学
- 癌症新陈代谢 癌症新陈代谢
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 代谢学和表观遗传学对质瘤的发展至关重要,它们会影响染色体结构.
- 像糖解和TCA循环这样的代谢途径调节表观遗传修饰,包括甲基化和乙化.
- 成人和儿科质瘤都利用这些代谢-表观遗传相互作用促进瘤生长.
研究的目的:
- 阐明癌症新陈代谢与质瘤表观遗传调节之间的相互作用.
- 为了确定代谢变化如何驱动不同年龄组的质瘤进展.
- 探索针对这些代谢-表观遗传通路的治疗策略.
主要方法:
- 关于质瘤代谢和表观遗传学的当前文献的综述.
- 分析涉及表观遗传修饰的代谢途径 (例如,S-adenosyl metionin,α-ketoglutarate).
- 检查特定的质瘤亚型 (IDH野生型,IDH突变型,儿科质瘤) 和它们的代谢重新连接.
主要成果:
- 代谢线索通过甲基化和乙化等表观遗传修饰来塑造色素.
- IDH野生型质瘤高调糖解,而IDH突变型质瘤产生D-2HG,导致高甲基化.
- 儿科质瘤表现出明显的代谢重新连接以控制染色质状态.
结论:
- 代谢和表观遗传学之间的交叉是质瘤生物学的基础.
- 准代谢途径为质瘤提供了有前途的治疗途径.
- 诸如vorasidenib,ONC201和美特福林等药物显示出抑制瘤性染色体状态的潜力.
相关概念视频
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


